140836-69-7

Basic information

• Product Name: [4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE
• Synonyms: AKOS B033707;[4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE;4-(2-Morpholin-4-yl-ethoxy)benzylamine;(4-(2-Morpholinoethoxy)phenyl)MethanaMine
• CAS NO: 140836-69-7
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.31
• Mol File: 140836-69-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 391 °C at 760 mmHg
• Flash Point: 190.2 °C
• Appearance: /
• Density: 1.101 g/cm³
• Vapor Pressure: 2.55E-06mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: 2-8°C
• PKA: 9.29±0.10(Predicted)
• CAS DataBase Reference: [4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE(140836-69-7)
• EPA Substance Registry System: [4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE(140836-69-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 140836-69-7(Hazardous Substances Data)

Usage

General Description

"[4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE is a chemical compound containing a phenyl ring which is linked to a methylamine group through a morpholinoethoxy bridge. [4-(2-MORPHOLINOETHOXY)PHENYL]METHYLAMINE has potential applications in medicinal chemistry and drug development due to its unique structure and potential pharmacological properties. The presence of the morpholino group in the molecule suggests that it may have biological activity and could potentially be used as a building block for the synthesis of novel pharmaceutical compounds. Further research and development of this chemical may lead to the discovery of new therapeutic agents for the treatment of various diseases and conditions."

InChI:InChI=1/C13H20N2O2/c14-11-12-1-3-13(4-2-12)17-10-7-15-5-8-16-9-6-15/h1-4H,5-11,14H2

Upstream product

• 34334-04-8 4-(2-morpholinoethoxy)benzonitrile 

Downstream Products

• 128540-47-6 3,4,5-Trimethoxy-N-[4-(2-morpholin-4-yl-ethoxy)-benzyl]-benzamide 
• 34334-04-8 4-(2-morpholinoethoxy)benzonitrile 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines

A method for inhibiting neoplastic cells and related conditions by exposing them to substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo?3,4-B!quinolin-4-amines.

Synthesis, gastrointestinal prokinetic activity and structure-activity relationships of novel N-[[2-(dialkylamino)ethoxy]benzyl]benzamide derivatives

Novel N-[[2-(dialkylamino)ethoxy]benzyl]benzamide derivatives (II-1-51), derived from the structural modification of metoclopramide (1), were synthesized and examined for their pharmacological activities. Among them, N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide (II-34) which exhibited well balanced gastrointestinal prokinetic and antiemetic activities was selected as a new type of gastrointestinal prokinetic agent.